Randomized controlled trial: 456 eligible subjects have been collected, 343 in Naomaitai capsule group and 113 in hydergine tablet group.
随机对照试验：共完成合格病例456例，脑脉泰组343例，喜得镇组113例。
Objective: to observe the therapeutic effectiveness of Xueshuantong Injection together with Naomaitai Capsule in treating apoplexy sequelae.
目的：观察血栓通注射液合脑脉泰胶囊治疗中风后遗症的临床疗效。
应用推荐